We aimed to study the relationship between the disease status of acromegaly (biochemical control on the GH-IGF-1 axis), disease duration, types of treatment options applied, as well as other clinical and paraclinical parameters on the patient-reported QoL and symptoms severity. This evidence concerns the gene GH1 and acromegaly.